GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (STU:TCE2) » Definitions » Cyclically Adjusted PB Ratio

Celldex Therapeutics (STU:TCE2) Cyclically Adjusted PB Ratio : 1.43 (As of May. 30, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Celldex Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-05-30), Celldex Therapeutics's current share price is €31.40. Celldex Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €22.00. Celldex Therapeutics's Cyclically Adjusted PB Ratio for today is 1.43.

The historical rank and industry rank for Celldex Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:TCE2' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.05   Med: 1.31   Max: 15.8
Current: 1.41

During the past years, Celldex Therapeutics's highest Cyclically Adjusted PB Ratio was 15.80. The lowest was 0.05. And the median was 1.31.

STU:TCE2's Cyclically Adjusted PB Ratio is ranked better than
54.89% of 654 companies
in the Biotechnology industry
Industry Median: 1.74 vs STU:TCE2: 1.41

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Celldex Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was €11.706. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €22.00 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Celldex Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Celldex Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celldex Therapeutics Cyclically Adjusted PB Ratio Chart

Celldex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.59 1.34 1.57 1.59

Celldex Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.29 1.24 1.03 1.59 1.74

Competitive Comparison of Celldex Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Celldex Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celldex Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Celldex Therapeutics's Cyclically Adjusted PB Ratio falls into.



Celldex Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Celldex Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=31.40/22
=1.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celldex Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Celldex Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=11.706/131.7762*131.7762
=11.706

Current CPI (Mar. 2024) = 131.7762.

Celldex Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 32.765 100.560 42.936
201409 31.154 100.428 40.879
201412 28.739 99.070 38.227
201503 52.854 99.621 69.914
201506 46.907 100.684 61.392
201509 43.169 100.392 56.665
201512 40.479 99.792 53.453
201603 35.481 100.470 46.537
201606 31.524 101.688 40.852
201609 28.656 101.861 37.072
201612 31.319 101.863 40.516
201703 27.992 102.862 35.860
201706 24.252 103.349 30.923
201709 20.877 104.136 26.418
201712 21.628 104.011 27.401
201803 11.377 105.290 14.239
201806 10.496 106.317 13.009
201809 9.771 106.507 12.089
201812 9.120 105.998 11.338
201903 7.765 107.251 9.541
201906 6.548 108.070 7.984
201909 5.788 108.329 7.041
201912 4.986 108.420 6.060
202003 4.272 108.902 5.169
202006 5.416 108.767 6.562
202009 4.935 109.815 5.922
202012 4.345 109.897 5.210
202103 4.117 111.754 4.855
202106 3.819 114.631 4.390
202109 7.955 115.734 9.058
202112 7.944 117.630 8.899
202203 7.731 121.301 8.399
202206 7.385 125.017 7.784
202209 7.408 125.227 7.795
202212 6.524 125.222 6.865
202303 5.985 127.348 6.193
202306 5.421 128.729 5.549
202309 4.891 129.860 4.963
202312 7.042 129.419 7.170
202403 11.706 131.776 11.706

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Celldex Therapeutics  (STU:TCE2) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Celldex Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Celldex Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Celldex Therapeutics (STU:TCE2) Business Description

Traded in Other Exchanges
Address
53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Celldex Therapeutics (STU:TCE2) Headlines

No Headlines